AMLprofiler chip new

The Most Efficient Diagnosis of Acute Myeloid Leukemia.

The AMLprofiler simplifies the challenging task to recognize Acute Myeloid Leukemia subtypes and make individualized therapy decisions. It delivers faster results and improved patient classification on an integrated and validated array platform.


In the USA the AMLprofiler is available for research use only.

  • graphicbestclassification2

    Best Classification

    Re-classification of more than 50% of the intermediate risk group and full identification of the favorable group with one test.

    Read more
  • nineassays

    Nine assays in one

    The AMLprofiler replaces 9 separate assays based on 3 different technologies: cytogenetics, mutation analysis and expression analysis.

    Read more
  • graphic3days2diagnose

    Three days to diagnosis

    Use of the AMLprofiler significantly reduces the time between sampling and diagnosis down to 3 days.

    Read more
  • Validated technology

    Skyline Diagnostics has developed the AMLprofiler under QA, featuring a standardized procedure on FDA-cleared Affymetrix™ platform

    Read more
  • graphiccertificate

    Clear report

    The AMLprofiler comes with a secure data analysis service, returning to you a clear and easily interpretable report.

    Read more
  • Workflow

    The straightforward 5-step AMLprofiler workflow requires only three days

    Read more
  • Technical data

    Age at diagnosis 18 years or older, cytopathologically confirmed diagnosis of AML (including APL and MDS) or RAEB according to the WHO 2008 classification, primary, secondary or relapse, no prior allogeneic or autologous stem cell transplant, no Myeloproliferative Syndrome (MPS)

    Read more

Dr. Molewaterplein 50, Suite Ee-1540, 3015 GE Rotterdam. The Netherlands, Europe. Phone: +31 (0)10 70 43 491. Fax: +31 (0)10 70 44 161. E-mail: